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RESEARCH ARTICLEDonor Variability in Growth Kinetics of Healthy hMSCs
Using Manual Processing: Considerations for
Manufacture of Cell TherapiesGiulia Detela, Owen W. Bain, Hae-Won Kim, David J. Williams, Chris Mason,
Anthony Mathur, and Ivan B. Wall*Human mesenchymal stromal cells (hMSCs) are excellent candidates for cell
therapy but their expansion to desired clinical quantities can be compromised
by ex vivo processing, due to differences between donor material and process
variation. The aim of this article is to characterize growth kinetics of healthy
baseline “reference” hMSCs using typical manual processing. Bone-marrow
derived hMSCs from ten donors are isolated based on plastic adherence,
expanded, and analyzed for their growth kinetics until passage 4. Results
indicate that hMSC density decreases with overall time in culture (p< 0.001)
but no significant differences are observed between successive passages after
passage 1. In addition, fold increase in cell number dropped between passage
1 and 2 for three batches, which correlated to lower performance in total fold
increase and expansion potential of these batches, suggesting that prolifer-
ative ability of hMSCs can be predicted at an early stage. An indicative
bounded operating window is determined between passage 1 and 3 (PDL
< 10), despite the high inter-donor variability present under standardized
hMSC expansion conditions used. hMSC growth profile analysis will be of
benefit to cell therapy manufacturing as a tool to predict culture performance
and attainment of clinically-relevant yields, therefore stratifying the patient
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Human mesenchymal stromal cells
(hMSCs) are attractive candidates for a
wide number of cell-based therapies due to
their multi-modal properties. They are able
to differentiate along mesenchymal line-
ages and can stimulate host tissue regen-
eration in a paracrine fashion.[1,2]
Althoughtheprimarysourceforderivation
is the bone marrow, hMSCs account only for
the 0.001–0.01% of the total mononuclear
cells present in that tissue[3] and their
frequency declines with aging.[2] This is of
major signiﬁcance, given that most hMSC-
based therapies are likely to be required for
medical conditions that increase in preva-
lence with increasing age. Therefore, to
obtain clinically relevant yields of cell product
forautologouscell therapy (whichvarygreatly
from 106–108 cells per patient depending on
injection site and treated indication), the ﬁrst
bioprocessing substantial challenge is the ex
vivo expansion of hMSCs that retain desired
functional properties (e.g., differentiation
and paracrine ability), while limiting thed Institute of Tissue
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www.advancedsciencenews.com www.biotechnology-journal.comimpact of the heterogeneity present among different individuals
hMSCs. Further, a standardized manufacturing with a process
window capable of accommodating input variations due to
differences in starting materials is required. Being able to quantify
expansion potential in vitro is important for understanding which
subsets of patients are likely to beneﬁt therapeutically, based on
producing enough cells. Subsequently being able to stratify patients
on that basis will improve clinical trial outcomes and reduce overall
therapy development costs.
Many protocols exist for hMSC harvest, seeding density, and
expansion, yielding signiﬁcant differences in expansion and
functional properties.[4] The conventional procedure for bone
marrow-derived hMSCs involves direct establishment of
cultures from total tissue aspirates, starting with density
centrifugation of the mononuclear cell population and hMSC
selection by adherence to plastic. Alternative methods may
include immunomagnetic selection based on cell surfacemarker
presence.[5] Once adhered, proliferating hMSCs have a spindle-
like morphology and are composed by multiple stromal
progenitor cells.[6]
The ISCTcriteria deﬁned hMSCs based on the adherence to
cell culture plastic, surface marker proﬁle, and capacity to
undergo tri-lineage differentiation in vitro.[7] Moreover,
additional markers are routinely used to identify bone
marrow hMSCs, including CD44/HCAM,[8] STRO-1,[9] and
CD146/MCAM.[10,11]
hMSC expansion potential is limited under standard manual
processing, to the extent that changes in growth rate and the
associated changes in identity and potency render hMSC
therapeutic value questionable beyond ﬁve passages,[12,13] or
beyond 20 population doublings (PDs),[14] with PDs being
considered a more reliable and accurate indicator of cell age. As
autologous cell products for diseases with systemic causes may
yield hMSCs whose quality varies according to the patient
severity of the disease, it can be even more difﬁcult to deﬁne
robust bioprocesses for autologous hMSCs because of biologic
variation between patients.[14]
Before trying to create processes that can accommodate poor
quality cells from diseased individuals, it is necessary to develop
processes using hMSCs from healthy donors, to deﬁne whether
that process can accommodate variability across healthy
donors. Insights gained will then prove useful when screening
patients to identify who will likely not beneﬁt from autologous
hMSC transplantation due to poor cell expansion potential.
Therefore, the aim of this study was to indicate the degree of
variability in hMSC growth kinetics across multiple healthy
donors when using manual processing that is typical for
autologous hMSCs.2. Experimental Section
2.1. Human Bone Marrow Mesenchymal Stromal Cell
Isolation
Cryopreserved bone marrow bags were received from 10
human male donors, aged between 16 and 18. The Research
Ethics Committee (REC) responsible was Central London REC
4 and the Joint UCL/UCLH Ethic Committee ReferenceBiotechnol. J. 2018, 13, 1700085 1700085 (2 of 10) © 2018 The ANumber for the project is REC 03/0136. Each bag contained
80–120mL of aspirate. The following procedure refers to an
aspirate of 100mL. Thawed bone marrow was diluted with
100mL of 1 Ca2þ/Mg2þ-free sterile PBS (Sigma–Aldrich,
Poole, UK) containing 1% Anti/Anti (Invitrogen, Paisley, UK).
A total of 20mL suspension aliquots were added to the surface
of 30mL of Ficoll-Paque PLUS (GE Healthcare, Little
Chalfont, UK). Centrifugation was performed at 650g for
30min at 20 C without acceleration and brakes. The
mononuclear cell phases were washed by centrifugation for
15min with a total of 120–150mL sterile 1 PBS/5% Anti/
Anti. Cell pellets were pooled in complete medium,
formulated with low glucose DMEM (supplemented with
Glutamax, Sodium Pyruvate, and Phenol Red, Invitrogen),
10% FBS (Sera Laboratories International, Haywards Heath,
UK), 1 ngmL1 recombinant hFGF-2 (R&D Systems, Minne-
apolis, MN, USA) and 1% Anti/Anti. Cells were seeded at
1 104 cells/cm2 density in T75 ﬂasks (Nunc, Roskinlde,
Denmark) and maintained in atmospheric oxygen in a 5%
CO2 humidiﬁed incubator.2.2. hMSC Expansion
hMSCs were maintained in culture with 15–20mL of complete
medium/T75 ﬂask. Non-adherent cells were removed on day 6.
The ﬁrst visible hMSC colonies were labelled as passage 0 (p0).
Complete medium was replaced every 3 days at each passage.
Daily observation of the cultures was performed with an inverted
light microscope (Eclipse50i, Nikon). Once p0 hMSCs reached
90% conﬂuence, they were detached using 0.25% trypsin/
EDTA (Sigma–Aldrich), counted using a hemocytometer and
plated into passage 1 (p1). Passaging was performed according to
a 1:3 ratio and expansion was carried throughout the end of
passage 4 (p4).2.3. Tri-lineage Differentiation
p2 hMSCs were induced in 12-well plates (Corning, NY, USA)
using commercial differentiation medium. All cultures were fed
every 3 days with 1mL of differentiation medium. Control
hMSCs cultures were processed in parallel using complete
medium.2.3.1. Adipogenic Differentiation
hMSCs were seeded at 1 104 cells/cm2 in complete growth
medium for 2 h. Cells were washed in 1 PBS and Adipogenesis
Differentiation Medium (StemPro Adipogenesis Differentiation
Kit, Invitrogen) was added. On day 14 cells were washed in 1
PBS and ﬁxed at room temperature for 10min with 4% PFA
(Sigma–Aldrich). Cells were rinsed with distilled water, then
permeabilized with 60% isopropanol (VWR International Ltd,
Poole, UK) for 5min and stained with a ﬁltered solution of 0.3%
w/vOil Red O (Sigma–Aldrich)/isopropanol in distilled water 3:2
for 5min, rinsed under tap water and counterstained with
hematoxylin (Sigma–Aldrich).uthors. Biotechnology Journal Published by WILEY-VCH Verlag GmbH & Co. KGaA
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hMSCs were seeded at 5 103 cells/cm2 with complete medium
for 2 h. The medium was replaced with Osteogenesis Differentia-
tion Media (StemPro Osteogenesis Differentiaiton Kit, Invitro-
gen). On day 21, they were washed in 1 PBS, ﬁxed with 4% PFA
for 30min at room temperature and rinsed with distilled water. A
2% Alizarin Red S solution (Sigma–Aldrich) at pH 4.2 was added
for 5min prior to rinsing with distilled water.2.3.3. Chondrogenic Differentiation
hMSCs micromasses were generated by seeding 10mL of a
1.6 107 hMSC/mL suspension in a well of a 12-well plate. After
4 h, Chondrogenesis Differentiation Media (StemPro Chondro-
genesis DifferentiaitonKit, Invitrogen)was added. Onday 14 cells
werewashed in1PBS,ﬁxedat roomtemperature for 30minwith
4% PFA, rinsed and stained in 1% Alcian Blue solution (Sigma–
Aldrich) prepared in 0.1MHCl (Sigma–Aldrich) for 30min. Cells
were rinsed twice in 0.1M HCL and then with distilled water.2.4. Immunocytochemistry
p2 hMSCs were washed with PBS, ﬁxed in 4% PFA for 10min, and
incubated inblockingsolution (1%BSA [Sigma–Aldrich] inPBS) for
1hr at room temperature. Primary antibodies were used 1:100 in
blocking solution overnight at 4 C. Cells were washed in blocking
solution three times. Secondary antibodies were used 1:300 in PBS
for 45min. Nuclei were counterstained with DAPI (Life Technolo-
gies, Paisley, UK) 1:10 000 in PBS for 5min. All primary antibodies
(α-CD14: Mouse IgG1, MAB1219; α-CD19: Mouse IgG2a,
MAB1794; α-CD34: Mouse IgG1, MAB4211; α-CD44 (H-CAM):
Mouse IgG2a, CBL154; α-CD45: Mouse IgG2a, 05-1410; α-CD73:
Mouse IgG1K,MABD122;α-CD90:Mouse IgG1,CBL415;α-CD105:
Mouse IgG2a, 05-1424; α-CD146 (M-CAM): Mouse IgG1,
MAB16985; α-STRO-1: Mouse IgM, MAB4315) were purchased
fromMillipore,UK, secondary antibodies (Donkey α-Mouse IgG: A-
31570 and Goat α-Mouse IgM: A-21042) from Life Technologies.2.5. Flow Cytometry
p2 and p3 hMSCs were characterized using MSC Phenotyping
Kit (MACS,Miltenyi Biotec). Brieﬂy, 5 105 hMSC aliquots were
resuspended in 100mL of buffer (PBS 1, pH 7.2, 0.5% BSA,
2mM EDTA) and incubated at room temperature for 40min.
Following compensation, hMSCs were analyzed on BD
FACSCalibur (Becton Dickinson) at the Scientiﬁc Support
Services Facility of UCL Cancer Institute and Wolfson Institute
for Biomedical Research. Results were plotted with Summit v4.3
Software (Beckman Coulter Inc., Brea, CA, USA).2.6. Determination of Growth Kinetics
Proliferation was assessed via Trypan Blue (Sigma–Aldrich)
exclusion for each hMSC batch at each passage.Biotechnol. J. 2018, 13, 1700085 1700085 (3 of 10) © 2018 The A2.6.1. Doubling Time (Td)
Growth rate was measured for every batch between p1 and p4
and expressed in hours as Td, using (T–T0)log(2)/log(N/N0),
where T¼ total hours at harvest and T0¼hours at passage
initiation, N¼ total conﬂuent hMSC number and N0¼ total
initial hMSC number.2.6.2. Cell Density
Cell density was calculated as conﬂuent hMSC number over the
growth area in cm2.2.6.3. Calculation of Population Doubling Level (PDL)
Growth rate was also measured for every batch between p0 and
p4 as PDL, using (logN–logN0)/log2, whereN¼ conﬂuent hMSC
number and N0¼ seeded hMSC number.2.6.4. Fold Increase in Cell Number
This was calculated as the total hMSCs at p4 over the number of
total hMSCs at p0. Similarly, serial fold increase in cell number
was calculated as cell yield of each given passage number over
cell yield of the previous passage number.2.6.5. Expansion Potential
The growth rate that could potentially be reached at each
passage, provided the entire hMSC population from each donor
was processed, was calculated based on cell density at passage,
multiplied for the total growth area in cm2 according to a 1:3
splitting ratio.2.7. Statistical Analysis
Each batch was expanded one time and duplicate measurements
were performed on the same material. Results are presented as
mean standard deviation for individual hMSC donors and for
averaged data from all 10 donors, to represent inter-patient
variation. Data analysis was performed using one-way ANOVA
with post-hoc Bonferroni test on the software Prism (Version 6.0,
GraphPad Software, Inc). A p-value< 0.05 was considered
statistically signiﬁcant.3. Results
3.1. hMSC Characterisation
First, morphologic characterization of isolated hMSCs in tissue
culture ﬂasts was performed. The ﬁrst adherent cells were present
by day 6 (Figure 1Ai), at which point non-adherent cells were
removed (Figure 1Aii) and cells expanded until 90% conﬂuenceuthors. Biotechnology Journal Published by WILEY-VCH Verlag GmbH & Co. KGaA
Figure 1. hMSC characterization. Morphology of thawed hMSCs at day 6 (Ai), in a mixture with hematopoietic non-adherent mononuclear cells. The
latter were removed during medium exchange at day 6 (Aii). The hMSC monolayer became confluent after 21 days of culture (Aiii). At p2 (B) hMSCs
exhibited the characteristic spindle-like, tapered shape. At p4 (C) hMSCs acquired an enlarged aspect and disorganized distribution in the flask. Black
arrows indicate cells with enlarged morphology visible at p4. Immunphenotyping was performed to evaluate the expression of positive (D) and negative
(E) hMSC cell surface markers on cells isolated from bone marrow aspirates. Flow cytometry was performed to validate the hMSC phenotype (F). Data
are presented as the percentage of positive cells. The area shaded in lighter gray indicates the profile of the isotype controls. Histograms shown are
representative of GX08 and GX09 batches. hMSCs multi-lineage differentiation ability was assessed for adipogenesis (Gi), chondrogenesis (Gii) and
osteogenesis (Giii). Scale bars¼ 100mm (Ai-iii, Bii, Cii, D, E), 200mm (Bi, Ci), 50mm (Biii, Ciii, Giþiii), 2mm (Gii).
www.advancedsciencenews.com www.biotechnology-journal.com
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Figure 1. Continued.
www.advancedsciencenews.com www.biotechnology-journal.com(Figure 1Aiii). Up to p3, all batches exhibited hMSC characteristic
spindle-shaped morphology, with monolayers composed of tightly
aligned cells (Figure 1Bi-iii). p4 cell morphology coincided with an
increasingproportionof polygonal cells, exhibitinghigh cytoplasm-
to-nucleus ratio and cytoplasmic ﬁlaments evidence. p4 cells also
showed a disorganized spatial orientation (Figure 1Ci-iii).
Next, hMSCsurfacemarker characterizationwas conﬁrmed via
immunoﬂuorescence labeling using antibodies directed against
CD44,CD73,CD90,CD105,CD146, andSTRO-1antigen (positive
markers, Figure 1D) and against CD14, CD19, CD34, CD45
(negativemarkers,Figure1E).Flowcytometrywasused toquantify
expression using a reduced hMSC surface marker panel
(Figure 1F), indicating that the cell population expressedmarkers
associated tohMSCs (CD73: 98.15 2.25%;CD90:75.83 9.12%;
and CD105: 98.92 0.51%) and lacked markers associated with
the bonemarrowhematopoietic fraction (CD14, CD20,CD34, and
CD45: 0.93 0.02% combined expression).
Finally, in vitro multipotency ability of the batches was
conﬁrmed on p2 hMSCs, cultured under lineage-speciﬁc
induction medium. Lipid vesicles became evident as early as
day 9 in hMSCs grown in adipogenic medium. On day 14, Oil
Red O staining revealed presence of numerous lipid compart-
ments within the hMSC cytoplasm (Figure 1Gi). Chondrogenic
differentiation was instead performed by culturing hMSC as
micro-aggregates at a starting concentration of 1 107 cells/mL
in chondrogenic medium. After 21 days, Alcian Blue staining
determined positive proteoglycans synthesis by the micro-
aggregates (Figure 1Gii). Finally, hMSCs under osteogenic
culture conditions deposited calciﬁed matrix as conﬁrmed via
positive Alizarin S staining (Figure 1Giii).Figure 2. hMSCs were expanded according to a 1:3 splitting ratio. hMSCs
yields of confluent monolayers (black bars) were calculated through
Trypan Blue exclusion method before hMSCs suspensions were split and
re-inoculated in the subsequent culture passage (white bars). p¼ 0.0149;
p¼ 0.0015; p< 0.001;  p< 0.0001.3.2. hMSCs Yield Per Passage
hMSC batches isolated from different donors were arbitrarily
named GX01, GX02, GX03, GX04, GX05, GX06, GX07, GX08,
X27, and X35. Monolayer cultures were serially passagedBiotechnol. J. 2018, 13, 1700085 1700085 (5 of 10) © 2018 The Ausing a 1:3 splitting ratio. Growth kinetics was determined for
each batch across ﬁve passages (p0–p4). Figure 2 shows input
and output averages of hMSC counts in T75 culture ﬂasks.
Inoculated cell amounts averaged 4.79 105 3.97 104 total
cells put into p1, 4.03 105 5.34 104 into p2, 3.57 105
 6.22 104 into p3 and 3.26 105 5.69 104 into p4,
showing a decrease likely related to the non-ﬁxed seeding
density. However, the average hMSC number obtained from
conﬂuent monolayers decreased more signiﬁcantly over
passages: from 1.45 106 1.25 105 at p0, to 1.22 106
 1.70 105 at p1, 1.04 106 1.71 105 at p2, 9.33 105
 1.59 105 at p3, 7.47 105 2.72 104 at p4, indicating an
overall 48.5% average hMSC decrease from p0 to p4
expansion. Signiﬁcant differences were observed betweenuthors. Biotechnology Journal Published by WILEY-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comseveral groups but not between input hMSCs for p2 versus p3
and p3 versus p4, nor between output hMSCs for p1 versus p2
and p2 versus p3.3.3. Achievable hMSC Density
To better evaluate hMSC expansion, cell density was docu-
mented for each batch once hMSCs reached conﬂuency
(Figure 3A and B). All hMSC batches showed a decrease in
cell density, directly correlated to passage number increase.
Average cell density was 1.93 104 1.67 103 cells/cm2 at p0,
1.63 104 2.26 103 cells/cm2 at p1, 1.38 104 2.28 103
cells/cm2 at p2, 1.24 104 2.12 103 cells/cm2 at p3, whereas
the average yield was 9.96 103 1.15 103 cells/cm2 at p4.Figure 3. hMSC density over time in culture. Mean cell density significantly
except between p2 and p3 (A). Mean values were calculated from the cell
densities at p2 and p3, hMSC cultures exhibited higher density at p2 than a
difference was present between p2 and p3 hMSCs from a same don
value¼ 1.24 104 hMSCs/cm2 (bold line).  p< 0.001.
Biotechnol. J. 2018, 13, 1700085 1700085 (6 of 10) © 2018 The AThis suggests a highly signiﬁcant decrease between conﬂuent
hMSC cultures at passage 0 and at later culture passages (p0 vs.
p1, p2, p3, and p4) as well as between p1 versus p3 and p4 and p2
versus p4. Figure 3C shows individual isolation data relative to
the latter two passages, wheremodest inter-isolation variability is
present, but again cell density differences between p2 and p3
from a same donor are negligible.3.4. hMSC Proliferation and Expansion Potential
As directly correlated to cell proliferation, Td was employed to
elucidate hMSC growth rates. On average, the mean Td for all
batches equaled 94.36 37.62 h to reach p1, 72.75 31.55 h for
p2, 60.55 11.44 h for p3, and 77.39 24.76 h for p4. The widedecreased with culturing time (indicated as passage number) in all cases
density of each hMSC batch across five passages (B). When comparing
t p3 (C). This was observed in all isolations expanded, but no significant
or. Mean p2 value¼ 1.38 104 hMSCs/cm2 (dashed line); mean p3
uthors. Biotechnology Journal Published by WILEY-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comvariation observed across batches resulted in no statistically
signiﬁcant differences across mean Td values for each passage.
The highest Td to reach p2 was exhibited by GX06, GX07, GX05,
and GX08: this reﬂects a slower growth rate at p2 for these
batches, although their Td fell closer to the rest of the batches at
p3 (Figure 4A).
To further analyzehMSCgrowth rates, additionally to “passage”
analysis, hMSC counts were used to determine the population
doubling level (PDL) for all batches. PDL curves (Figure 4B) better
represent the cell growth rate and the in vitro age than passage
number, and its steady increase through expansion indicated that
hMSCs proliferated sustainably across all passages considered,
with all batches reaching an average PDL12 at p4.AlthoughPDL
values were comparable at each passage for each batch, the time
required varied. The slowest growth rate in terms of PDL over
culturing time was in GX01, GX07, and GX08.
Serial passage (Figure 5A) and population fold increase in cell
number (Figure 5B) across the ﬁve passages was calculated for
all hMSC batches. Seven batches displayed the highest serial
passage fold increase at p2, followed by p3, but we observed three
out of ten outliers (GX05, GX07, and GX08) for which this was
not true. Nevertheless, the overall trend across adjacent passages
for hMSC isolated from individual donors was consistent with
the observation of overall population fold increase in cell
number, where the same outliers were identiﬁed. Of note, no
statistically signiﬁcant differences were detected in overall fold
increase in cell number between donors.
Predicted hMSC expansion potential was measured as a
relationship of the total achievable yield after each passage
over time in culture. Individual expansion values are
expressed in Figure 5C. Total yields were deduced from the
hMSC density previously calculated, accounting for the 1:3Figure 4. hMSC doubling time population doublings achieved across
serial passages. Td curves between passages were calculated for each
hMSC batch across the four passages (A) and cumulative population
doubling level (PDL) was assessed for each donor over time up to passage
4 and was based on initial cell input and total cell output (B).
Biotechnol. J. 2018, 13, 1700085 1700085 (7 of 10) © 2018 The Apassage ratio which would be used for hMSC re-seeding at
each passage. Figure 5D presents the average expansion yields
for all batches, with p0 yielding on average 2.82 106 2.03
 105 hMSCs, p16.23 106 1.75 106, p217.29 106
 5.19 106, p350.40 106 8.59 106, and p4121.01
 106 13.9 106. These data, together with the previous
on actual growth kinetics, allowed us to conclude that a
positive proliferation and expansion potential intrinsically
characterized all ten hMSC batches at least until the
completion of passage 4, but also that cell size and
morphology vary substantially with cell expansion.4. Discussion
This study describes the expansion and achievable hMSC yields
from a pool of 10 different bone marrow young male donors
aged 16–18 years old. The goal was to characterize growth
kinetics of healthy baseline “reference” hMSCs using typical
manual processing. The actual patient populations requiring
hMSC therapies will likely be of wide age range and suffer from
illness, so inter-patient variability in quality of cell material will
result from age and disease status. Other sources of variability in
hMSC quality arise from variability in isolation and processing
protocols.[15] Therefore, the rationale underlying our work was to
address observe process variability independent of donor age and
gender.
Although some hMSC culture strategies can employ ﬁxed low
seeding density to limit senescence onset,[16,17] here we used a
ﬁxed splitting ratio (1:3) typically used for primary somatic cell
cultures. hMSCs from all batches displayed morphology typical
of early progenitors[18] when maintained in culture until the end
of p3. Notably, although no signiﬁcant differences were detected,
the lowest Td was observed for p3 cultures (PDL8–10),
suggesting that, overall, at this stage hMSCs had the fastest
growth rate.
When hMSCs are expanded in vitro, they are affected by
processing variables, including cell seeding density and oxygen
tension,[19] and also encounter replicative senescence[20] due to
loss of the physiologic niche where they resided quiescent. In
vitro culture conditions (e.g., plastic adhesion, exposure shear
forces during pipetting, media reagents, detaching enzymes,
etc.) can accelerate aging and loss of function.[21,22] Strategies to
limit senescence and loss of functionality include processing
under reduced oxygen tension[23] or in presence of growth
factors such as FGF-2,[24,25] as was performed in this study.
Even when employing a ﬁxed seeding density for primary cells
at p0, we measured a substantial amount of variability in the
time taken to initiate cell doublings, likely reﬂecting variability in
hMSC viability at seeding. This may be further affected if the
cells are cryopreserved, as was the case in this study . Critically,
cell identity markers need to be at a consistently acceptable level.
The ten batches processed displayed hMSC markers, although
CD90 showed some variability relative to the other markers,
suggesting that it may be a critical marker of product quality.
Indeed, CD90 expression was demonstrated to regulate hMSC
differentiation ability.[26] However, this did not appear to impact
on any of the donor hMSC’s ability to undergo tri-lineage
differentiation.uthors. Biotechnology Journal Published by WILEY-VCH Verlag GmbH & Co. KGaA
Figure 5. Fold increase in cell number and expansion potential of start population. Fold increase in cell number between serial passages was consistent
for all the hMSC batches isolated except for GX05, GX07, and GX08 (A). Overall fold increase across five passages, from p0 and p4, is shown for all hMSC
batches (B), where the mean across donors was 42.06 (bold line). No statistical differences were detected between hMSC batches. Expansion potential
across five passages was calculated for each individual donor (C) and averaged across donors (D).
www.advancedsciencenews.com www.biotechnology-journal.comThe decrease in cell density at harvest correlated with
morphological observation of cell enlargement at p4 (PDL> 10,
Td77.3h) for all batches, likely due to in vitro cell aging. This
corroborates a recent report by Whitﬁeld et al.,[27] who reported
hMSC size increase over time due to exit from the cell cycle.
Statistically signiﬁcant differences in cell density (p< 0.001) were
observed between p4 versus p0 and p1 (PDL2.9, Td94h),
conﬁrming that cells slow andbecome senescent over time and that
the number of rapidly dividing progenitors was dramatically
reduced by p4 compared with previous passages. However, PDL
measurements indicate that hMSCs expansion was faster between
p1 and p3 (PDL8.8, Td60h), so the decreasing output cell yields
recorded are presumably also partly a function of increased passage
frequency. hMSCs from three donors (GX05, GX07, and GX08)
exhibitedamorepronounceddropincelldensitybetweenp1andp2,
possibly because of earlier onset of senescence in these batches
because ofmore rapidmaturation in culture. In fact, it was between
p1 and p2 (PDL5.8, Td72h) that the most heterogeneous fold
increase in cell number was noted across batches and hence where
process monitoring and control is most likely needed to identify
potential failures earlier in the process. This could be achieved by
implementing in-process monitoring that could include real-time
morphology assessment, time-lapse documentation of population
dynamics and off-line monitoring of metabolites.
Nevertheless, in this study PDL and fold increase in cell
numbers from p0 to p4 indicated constant growth of hMSCs
from all donors. Interestingly, two of the three outliers (GX07Biotechnol. J. 2018, 13, 1700085 1700085 (8 of 10) © 2018 The Aand GX08) for cell density between p1 and p2 had the slowest
growth rates as measured via PDL, and consequently the
estimated proliferation potential of the population might be
substantially impaired compared to the other batches. This
observation also correlated with a longer doubling time required
for the two outliers to reach p3.
Donor age and gender may both impact on hMSC
proliferation ability. It has been recently reported that bone
marrow-derived hMSCs originating from young (<45 years old)
female donors have a slight but signiﬁcantly reduced Td
compared to young male donors.[28] Using hMSCs isolated
from relatively young male donors, we measured cell prolifera-
tion ability via PDL, representing the number of total population
doublings since their initiation in vitro. It is clear that assessing
either PDL or Td in hMSCs isolated from young donors will
provide a real measure of which cultures possess higher
expansion potential in vitro.[13,20,28–30] Based on the cell density,
PDL and fold increase data, at p2 and p3 young male donor
hMSCs share similar growth kinetics proﬁles. Finally, expansion
potential was calculated for the different hMSC isolations up to
p4 to determine theoretical yield of cells that could be achieved.
The highest yield measured among all ten batches at p2 and p3
was almost twice (GX06, p22.33 107 cells/cm2 and p36.59
 107 cells/cm2) the lowest yield obtained (GX07, p21.39 107
cells/cm2 and p33.74 107 cells/cm2), indicating the variabil-
ity range of hMSC yields that might be expected for the
generation of autologous cell therapy products.uthors. Biotechnology Journal Published by WILEY-VCH Verlag GmbH & Co. KGaA
www.advancedsciencenews.com www.biotechnology-journal.comAll ten independent donor hMSCs characterized for growth
potential in this paper displayed similar growth kinetics proﬁles
in terms of declining achievable density at harvest. This suggests
that deﬁning a process operating window based on a
representative range of healthy donor samples should be
feasible to enable expansion of autologous cells for therapy
using manual processing. If manufacturing predictions on the
range of achievable hMSC yields can be made early in the
expansion phase, that is, in a p1–p3 operating window
(PDL< 10), then overall resource requirements and process
risks can be reduced for both industry and patient beneﬁt. The
degree of heterogeneity between batches from p1 to p2 observed
in this study indicates that it may be feasible to predict success or
failure earlier on in the process. However, the current data, at
n¼ 10, represents a relatively small sample size and therefore
greater numbers of primary hMSC batches would need to be
tested to validate these observations.
hMSCexpansion potential is critical for achieving clinical scale.
In this context, thereal challenge isachievingclinically relevantcell
numbers before hMSC progenitor phenotype is lost beyond
passage 4. Our data show that by expanding hMSCswith standard
protocols outlined in this study, p2 and p3 cells could give rise to
early-progenitor hMSCs populations that could be expanded for
clinical applications. However, development of functional tests to
deﬁne mode of action, for example, paracrine signaling, vascular
support, is required to conﬁrm cell product quality.
Nevertheless, as the process is brought toward product
development, the expansion requirements can dramatically
increase to reach adequate clinical levels. By taking cardiovascular
diseases as an exemplar due to their incidence and lethality
worldwide, there is a smallbodyof literatureonearly-phase clinical
studiesassessingautologoushMSCs for therapeuticpotency inMI
patients.[31–35] Although these studies are different in a variety of
parameters, such as patient inclusion criteria, cell deliverymethod
as well as outcome measurements, the total cell number infused
per dose was never lower than 5 106. Where cells in the order of
106–107 are required, the processing strategies reported here, that
can yield on average 17 106 cells at p2 and 50 106 at p3, would
appear to be an attractive route forward. However, in the
POSEIDON trial[35] the greatest therapeutic beneﬁt was seen
withmultipleadministrationsof20 106hMSCsperdoseandthis
suggests, along with other estimates[36] that up to 108 cells per
patient will be required.
It can be assumed that with a single 4-layer cell factory
(2528 cm2 cell expansion surface) a 33-fold increase in hMSC
yield (compared to a T75 ﬂask) can be achieved. Also, multilayer
ﬂasks reduce manual processing needs. However, moving
toward 108 cells per dose, it is not clear whether cell quality
would be maintained and so robust identity and functional
hMSC characterization tools, that to date are still lacking, will be
essential to better understand potency of the cells and differ-
ences in potency between individual patients.Abbreviations
DAPI, 40,6-diamidino-2-phenylindole; EDTA, thylenediaminetetraacetic
acid; hMSC, human mesenchymal stromal cell; PBS, phosphate buffer
saline; PDL, population doubling level; PFA, paraformaldehyde; Td,
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